
## Treating Cancer X in the EU5

We compared the use of a certain treatment for Cancer X across the EU5 nations of France, Germany, Italy, Spain, and the UK in a retrospective landscape treatment study using chart audits. We found that although physicians reported they most often follow guidelines, few of them said they always use guideline-recommended Treatment X. Actual chart data confirmed underuse of this treatment, and we found wide variations between nations in its use. We also found disparities between nations in how many study physicians had completed specialized oncology fellowships and in physicians' volume of Cancer X cases. We recommended country-specific efforts to promote use of Treatment X.





| Physicians at a Glance  |   |  |  |   |   |                                |
|---|---|--|--|---|---|--------------------------------|
| Attribute   | France (A)                                  | Germany<br>(B)                             | Italy<br>(C)                                 | Spain (D)                                   | UK<br>(E)                                   | EU5                            |
| Mean number of years qualified in specialty   | 10.3  | 13.3                                       | 13.5   | 14.1  | 11.3  | 12.6                           |
|   |   |  |  | Α   |   |                                |
| Male  | 97%<br>B                                    | 83%  | 89%  | 92%   | 94%   | 91%                            |
| Setting in which physician treats majority of Cancer X patients   | Б   |  |  |   |   |                                |
| Community office/community center/<br>nonteaching hospital  | 47%   | 75%  | 69%  | 40%   | 30%   | 52%                            |
|   |   | ADE  | ADE  |   |   |                                |
| University/academic hospital  | 53%   | 25%  | 31%  | 60%   | 70%   | 48%                            |
|   | BC  | 1  |  | BC  | BC  |                                |
| Completed fellowship in specialty X   | 95%   | 90%  | 90%  | 65%   | 46%   | 77%                            |
| % who report they follow guidelines (mean)  | 79.3%                                       | 79.2%                                      | 80.6%  | 80.0%                                       | 80.6%                                       | 79.9%                          |
|   | DE  | DE   | DE   |   |   |                                |
| Number of physicians  | 58  | 72   | 62   | 65  | 67  | 324                            |
| Patients at a Glance  |   |  |  |   |   |                                |
| Attribute   | France                                      | Germany                                    | Italy  | Spain                                       | UK  | EU5                            |
| Attribute   | France (A)                                  | Germany<br>(B)                             | Italy<br>(C)                                 | Spain (D)                                   | UK<br>(E)                                   | EU5                            |
| Attribute  Mean age   | (A)<br>66.7                                 | (B)<br>66.5                                |  | (D)<br>65.7                                 | (E)<br>68.1                                 | EU5<br>66.7                    |
| Mean age  | (A)<br>66.7<br>C                            | (B)<br>66.5<br>C                           | (C)<br>65.8                                  | (D)<br>65.7<br>C                            | (E)<br>68.1<br>B                            | 66.7                           |
|   | (A)<br>66.7<br>C<br>77%                     | (B)<br>66.5                                | (C)  | (D)<br>65.7<br>C<br>88%                     | (E)<br>68.1                                 |                                |
| Mean age Female   | (A)<br>66.7<br>C                            | (B)<br>66.5<br>C                           | (C)<br>65.8                                  | (D)<br>65.7<br>C                            | (E)<br>68.1<br>B                            | 66.7                           |
| Mean age  Female  Cancer subtype*   | (A)<br>66.7<br>C<br>77%<br>B                | (B)<br>66.5<br>C<br>72%                    | (C)<br>65.8<br>73%                           | (D)<br>65.7<br>C<br>88%<br>BCE              | (E)<br>68.1<br>B<br>74%                     | 66.7                           |
| Mean age Female   | (A)<br>66.7<br>C<br>77%                     | (B)<br>66.5<br>C                           | (C)<br>65.8                                  | (D)<br>65.7<br>C<br>88%                     | (E)<br>68.1<br>B                            | 66.7                           |
| Mean age  Female  Cancer subtype*   | (A)<br>66.7<br>C<br>77%<br>B                | (B)<br>66.5<br>C<br>72%                    | (C)<br>65.8<br>73%                           | (D)<br>65.7<br>C<br>88%<br>BCE              | (E)<br>68.1<br>B<br>74%                     | 66.7                           |
| Mean age  Female  Cancer subtype*  Subtype X  | (A) 66.7 C 77% B                            | (B)<br>66.5<br>C<br>72%                    | (C)<br>65.8<br>73%                           | (D)<br>65.7<br>C<br>88%<br>BCE              | (E) 68.1 B 74% 97% ABC                      | 66.7<br>77%<br>89%             |
| Mean age  Female  Cancer subtype*  Subtype X  | (A) 66.7 C 77% B                            | (B)<br>66.5<br>C<br>72%<br>88%             | (C)<br>65.8<br>73%<br>80%                    | (D)<br>65.7<br>C<br>88%<br>BCE              | (E) 68.1 B 74% 97% ABC                      | 66.7<br>77%<br>89%             |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX   | (A) 66.7 C 77% B 85%                        | (B)<br>66.5<br>C<br>72%<br>88%             | (C)<br>65.8<br>73%<br>80%                    | (D)<br>65.7<br>C<br>88%<br>BCE<br>91%       | (E)<br>68.1<br>B<br>74%<br>97%<br>ABC<br>4% | 66.7<br>77%<br>89%             |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage                              | (A) 66.7 C 77% B 85%                        | (B) 66.5 C 72% 88% 6% 15% C                | (C)<br>65.8<br>73%<br>80%<br>19%<br>BE<br>4% | (D) 65.7 C 88% BCE 91% 9%                   | (E) 68.1 B 74% 97% ABC 4%                   | 66.7<br>77%<br>89%<br>8%       |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX   | (A) 66.7 C 77% B 85%                        | (B)<br>66.5<br>C<br>72%<br>88%             | (C)<br>65.8<br>73%<br>80%                    | (D)<br>65.7<br>C<br>88%<br>BCE<br>91%       | (E)<br>68.1<br>B<br>74%<br>97%<br>ABC<br>4% | 66.7<br>77%<br>89%             |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage Stage Y                      | (A) 66.7 C 77% B 85% 85% 7% C               | (B) 66.5 C 72% 88% 6% 15% C                | (C)<br>65.8<br>73%<br>80%<br>19%<br>BE<br>4% | (D) 65.7 C 88% BCE 91% 9%                   | (E) 68.1 B 74% 97% ABC 4%                   | 66.7<br>77%<br>89%<br>8%       |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage                              | (A) 66.7 C 77% B 85% 85% 10%                | (B) 66.5 C 72% 88% 6% 15% C                | (C)<br>65.8<br>73%<br>80%<br>19%<br>BE<br>4% | (D) 65.7 C 88% BCE 91% 9%                   | (E) 68.1 B 74% 97% ABC 4% 8%                | 66.7<br>77%<br>89%<br>8%<br>9% |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage Stage Y                      | (A) 66.7 C 77% B 85% 8% 10% 7% C 65%        | (B) 66.5 C 72% 88% 6% 15% C 7% C 61%       | (C)<br>65.8<br>73%<br>80%<br>19%<br>BE<br>4% | (D) 65.7 C 88% BCE 91% 9%                   | (E) 68.1 B 74% 97% ABC 4% 8% 4%             | 66.7<br>77%<br>89%<br>8%<br>9% |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage Stage Y  Stage YY            | (A) 66.7 C 77% B 85% 8% 10% C 65% CD        | (B) 66.5 C 72% 88% 6% 15% C 7% C 61% D     | (C) 65.8 73% 80% 19% BE 4%                   | (D) 65.7 C 88% BCE 91% 9% 7%                | (E) 68.1 B 74% 97% ABC 4% 8% 63% CD         | 89%<br>89%<br>8%<br>9%         |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage Stage Y  Stage YY            | (A) 66.7 C 77% B 85% 8% 10% C 65% CD        | (B) 66.5 C 72% 88% 6% 15% C 7% C 61% D     | (C) 65.8 73% 80% 19% BE 4% 0% 45%            | (D) 65.7 C 88% BCE 91% 9% 7% 3% 29%         | (E) 68.1 B 74% 97% ABC 4% 8% CD 33% 71%     | 89%<br>89%<br>8%<br>9%         |
| Mean age  Female  Cancer subtype* Subtype X  Subtype XX  Subtype XXX  Cancer stage Stage Y  Stage YY  Stage YYY | (A) 66.7 C 77% B 85% 8% 10% 7% C 65% CD 28% | (B) 66.5 C 72% 88% 6% 15% C 7% C 61% D 32% | (C) 65.8 73% 80% 19% BE 4% 0% 45% ABE        | (D) 65.7 C 88% BCE 91% 9% 7% 3% 29% 68% ABE | (E) 68.1 B 74% 97% ABC 4% 8% CD 33%         | 66.7 77% 89% 8% 9% 4% 54%      |

Sums of subtypes exceed 100% because a patient may have more than 1 tumor. Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, the letter of the smaller category appears in the bar of the category with larger mean. Z tests for column proportions were adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni correction.

Private and confidential; no reproduction permitted; certain outputs of this example presentation were altered to protect client confidentiality